Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Russia says medics to get anti-COVID shots in two weeks, rejects safety concerns

Published 12/08/2020, 10:50
Updated 12/08/2020, 10:55
© Reuters. A handout photo shows samples of a vaccine against the coronavirus disease developed by the Gamaleya Research Institute of Epidemiology and Microbiology, in Moscow

MOSCOW (Reuters) - Russia said on Wednesday the first batch of its Covid-19 vaccine would be ready for some medics within two weeks and rejected as "groundless" safety concerns aired by some experts over Moscow's rapid approval of the drug.

President Vladimir Putin said on Tuesday that Russia had become the first country to grant regulatory approval to a COVID-19 vaccine, after less than two months of human testing.

The vaccine has not yet completed its final trials. Only about 10% of clinical trials are successful and some scientists fear Moscow may be putting national prestige before safety.

"It seems our foreign colleagues are sensing the specific competitive advantages of the Russian drug and are trying to express opinions that in our opinion are completely groundless," Health Minister Mikhail Murashko said on Wednesday.

He said the vaccine developed by Moscow's Gamaleya Institute would be administered to people, including doctors, on a voluntary basis, and would be ready soon.

"The first packages of the medical vaccine against the coronavirus infection will be received within the next two weeks, primarily for doctors," he said.

Alexander Gintsburg, director of the Gamaleya Institute, said clinical trials would be published once they have been assessed by Russia's own experts.

He said Russia plans to be able to produce 5 million doses a month by December-January.

Kazakhstan plans to send government officials to Moscow later this month to discuss possible deliveries of the vaccine, its presidential office said.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.